Multiple Sclerosis Drugs

Added to site March 2007

• Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
• Can super-antibody drugs be tamed?
• Natalizumab for Relapsing Multiple Sclerosis
• Interferon beta babies
• Therapeutic Considerations for Disease Progression in Multiple Sclerosis
• Campath treatment suspended after serious risks found
• High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
• What went wrong in the natalizumab trials?
• Regulatory CD56^bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
• Lessons for clinical trials from natalizumab in MS
• Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
• The reproductive effects of beta interferon therapy in pregnancy
• Severe anaphylactic reaction to glatiramer acetate with specific IgE
• Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis
• Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
• Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event
• Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
• History of modern multiple sclerosis therapy
• Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
• Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment
• A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
• The coming of age for antigen-specific therapy of multiple sclerosis
• Selective Treatment of Multiple Sclerosis
• Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
• Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

Added to site November 2005

• Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
• Neutralizing anti-IFN-β antibodies
• FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis
• Glatiramer Acetate Therapy: The Plot Thickens
• Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy
• Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
• Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
• Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
• Patients at Risk
• Natalizumab and Progressive Multifocal Leukoencephalopathy
• Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease
• Therapy with glatiramer acetate for multiple sclerosis
• Treatment of severe autoimmune disease by stem-cell transplantation
• Design of effective immunotherapy for human autoimmunity
• Novantrone Adverse Effects
• Fulminant liver failure during interferon beta treatment of multiple sclerosis
• Liver injury associated with the β-interferons for MS
• Liver injury associated with the β-interferons for MS (discussion)
• Low dose naltrexone therapy in multiple sclerosis
• Using stem cells in multiple sclerosis therapies
• Rebif Adverse Reactions
• Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
• Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
• Interferons in relapsing remitting MS
• Lack of evidence for use of glatiramer acetate in multiple sclerosis
• New directions in MS therapeutics: vehicles of hope
• The promise of minocycline in neurology
• Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD
• Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
• Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
• Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines
• Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
• Patterns of cannabis use among patients with multiple sclerosis
• Marijuana as a treatment for epilepsy and multiple sclerosis? A “grass roots” movement
• Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
• Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis
• Statins for the treatment of multiple sclerosis: cautious hope
• Oral simvastatin treatment in relapsing-remitting multiple sclerosis
• Suppressing immunity in advancing MS; Too much too late, or too late for much?
• Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS
• Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol
• Cost of Managing an Episode of Relapse in Multiple Sclerosis in the United States
• Future Immunotherapies in Multiple Sclerosis
• Therapeutic potential of lovastatin in multiple sclerosis
• Silencing Autoimmunity in Multiple Sclerosis, Lupus, and Rheumatoid Arthritis
• Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre
• Is nalalizumab a breakthrough in the treatment of MS?
• Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
• Interferons in relapsing remitting multiple sclerosis: a systematic review
• Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
• A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
• Key issues in the diagnosis and treatment of multiple sclerosis
• Mycophenolate-Mofetil May Stabilize Patients with Progressive Multiple Sclerosis
• Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained
• Needed in MS Evidence, not EVIDENCE
• Randomized, comparative study of interferon β-1a treatment regimens in MS The EVIDENCE Trial
• CME A randomized, double-blind, dosecomparison study of weekly interferon β-1a in relapsing MS
• The Janus face of CNS-directed autoimmune response: a therapeutic challenge
• Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
• Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses
• Tackling multiple sclerosis
• Growth factor treatment of demyelinating disease: at last, a leap into the light
• Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS
• Statins as immunomodulators; Comparison with interferon-β1b in MS
• Daclizumab Zenapax inhibits early interleukin-2 receptor signal transduction events
• Immunotherapies: cause for measured optimism
• Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol
• Nascobal
• Transdermal Histamine in Multiple Sclerosis, Part Two: A Proposed Theoretical Basis for Its Use
• Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis
• Multiple Sclerosis: Update on Treatment
• Cholesterol drug counters MS symptoms in mice
• Current Therapy of Multiple Sclerosis
• Intravenous immunoglobulin in neurological disease: a specialist review
• Modafinil Is Safe and Effective Treatment for MS-Related Fatigue
• A prospective, open-label treatment trial to compare the effect of IFN β-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
• Disease modifying therapies in multiple sclerosis
• A randomized, double-blind, placebocontrolled MRI study of anti–herpes virus therapy in MS
• Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
• Preventing multiple sclerosis?
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in MS